Voltage-gated potassium channels as therapeutic targets

Wulff, H.; Castle, N. A.; Pardo, L. A.

doi:nrd2983 [pii]
10.1038/nrd2983

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Voltage-gated potassium channels as therapeutic targets

MPS-Authors

Wulff, H.
Max Planck Society;

Castle, N. A.
Max Planck Society;

Pardo, L. A.
Max Planck Society;

External Resource

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19949402
(Any fulltext)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Wulff, H., Castle, N. A., & Pardo, L. A. (2009). Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov, 8(12), 982-1001. doi:nrd2983 [pii] 10.1038/nrd2983.

Cite as: https://hdl.handle.net/21.11116/0000-0009-F22D-4

Abstract

The human genome encodes 40 voltage-gated K(+) channels (K(V)), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca(2+) signalling and cell volume, to driving cellular proliferation and migration. K(V) channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting K(V) channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K(V)1 subfamily, the K(V)7 subfamily (also known as KCNQ), K(V)10.1 (also known as EAG1 and KCNH1) and K(V)11.1 (also known as HERG and KCNH2) channels.